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The molecular sensors underlying nutrient-stimulated GLP-1 secretion are currently being
investigated. Peripheral administration of melanocortin-4 receptor (MC4R) agonists have been
reported to increase GLP-1 plasma concentrations in mice and humans but it is unknown
whether this effect results from a direct effect on the GLP-1 secreting L-cells in the intestine,
from other effects in the intestine or from extra-intestinal effects. We investigated L-cell
expression of MC4R in mouse and human L-cells by reanalyzing publicly available RNA
sequencing databases (mouse and human) and by RT-qPCR (mouse), and assessedwhether
administration of MC4R agonists to a physiologically relevant gut model, isolated perfused
mouse and rat small intestine, would stimulate GLP-1 secretion or potentiate glucose-
stimulated secretion. L-cell MC4R expression was low in mouse duodenum and hardly
detectable in the ileum and MC4R expression was hardly detectable in human L-cells. In
isolated perfused mouse and rat intestine, neither intra-luminal nor intra-arterial administration
of NDP-alpha-MSH, a potent MC4R agonist, had any effect on GLP-1 secretion (P ≥0.98, n =
5–6) from the upper or lower-half of the small intestine in mice or in the lower half in rats.
Furthermore, HS014—an often usedMC4R antagonist, which we found to be a partial agonist
—did not affect the glucose-induced GLP-1 response in the rat, P = 0.62, n = 6). Studies onn.org August 2021 | Volume 12 | Article 6903871
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Frontiers in Endocrinology | www.frontiersitransfected COS7-cells confirmed bioactivity of the used compounds and that concentrations
employed were well within in the effective range. Our combined data therefore suggest that
MC4R-activated GLP-1 secretion in rodents either exclusively occurs in the colon or involves
extra-intestinal signaling.Keywords: alpha-MSH, melanocortin, melanocortin-4-receptor, glucagon-like peptide-1 secretion, L-cellsINTRODUCTION
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone
that is secreted from intestinal L-cells after meal intake. It acts to
inhibit appetite and potentiate glucose-stimulated insulin
secretion (1–3). These actions led to the development of GLP-1
based drugs, which have been used for more than a decade for
type-2-diabetes treatment and recently also to induce weight loss.
In parallel with the development and refinement of GLP-1 based
drugs, research has been directed at uncovering the molecular
mechanisms responsible for GLP-1 secretion, aiming to create a
therapeutically relevant stimulation of endogenous L-cell
secretion by pharmacological means (4, 5). Compared to GLP-1
mono-therapy, this approach would be expected to result in
improved weight loss since GLP-1 often co-localizes with the
anorectic hormones cholecystokinin and peptide-YY (6–9),
potentially leading to a synergistic inhibitory effect on appetite
during L-cell stimulation. The molecular mechanisms
underlying macro-nutrient stimulated GLP-1 secretion have
been studied by several laboratories during the last two
decades and consensus models for at least some nutrients, e.g.
glucose, have been reached (5). However, regulation of secretion
also includes potential endocrine, paracrine and neural inputs
and several aspects need clarification. It has been suggested that
peptide hormones, derived from pro-opiomelanocortin (POMC)
may regulate GLP-1 secretion by binding to MC4R expressed by
the L-cell. Thus, in one study, MC4R was found to be the second
most highly enriched receptor expressed by mouse L-cells
(compared to non-L cells from same anatomical site), and the
synthetic MC4R agonist, LY2112688 (10), was found to increase
plasma GLP-1 and PYY concentrations in mice in vivo after
intra-peritoneal injection (11). A similar observation was
recently made by Panaro et al., who also showed LY2112688-
mediated increase in plasma GLP-1 concentrations in mice.
Furthermore, they showed that the increase requires gcg
expression in the ileum and colon (12), pointing towards that
these sites of the intestine are responsible for the increased
plasma concentrations. Moreover, it has been shown that
humans with natural occurring loss-of-function mutations in
MC4R exhibit reduced plasma PYY levels (marker of L-cell
secretion from the distal intestine) in response to an OGTT,
and GLP-1 and PYY secretion from human gut specimens
(obtained from duodenum, ileum and colon) increased in
response to incubation with the MC4R agonists MK-0493,
LY2112688, a-MSH and NDP-a-MSH (13).n.org 2Importantly, these reported effects of pharmacological MC4R
agonism appear to translate to humans as continuous
subcutaneous infusion over 72 h of another MC4R agonist,
RM-493, increased plasma GLP-1 concentrations by 50–100%
(14). However, while these studies are intriguing and show that
MC4R agonists may increase plasma GLP-1 concentrations, they
do not reveal whether this action results from direct stimulatory
actions on MC4Rs expressed on the L-cell or from other indirect
actions. Further studies are needed to investigate this and it also
needs to be clarified from which source(s) and under which
circumstances MC4R agonists are released physiologically and
how any daily dynamics in release relate to daily fluctuations in
plasma GLP-1 levels. We therefore investigated MC4R
expression in mouse and human intestinal L-cells and
investigated whether the MC4R ligand, NDP-a-MSH, would
stimulate GLP-1 secretion in a physiologically relevant gut
model, the isolated perfused mouse and rat small intestine.
Furthermore, using the same model, we investigated whether
acute application of the described MC4R antagonist, HS014,
would inhibit basal GLP-1 and/or glucose-stimulated GLP-1
secretion in the rat. In addition, we characterized the
concentration–response relationship between a-MSH and
human MCR4 activation, and compared this to published
peripheral plasma concentrations of a-MSH in humans to
assess whether circulating a-MSH levels are sufficient to
directly interact with and activate MC4R on L-cells.MATERIALS AND METHODS
Ethical Considerations
The isolated perfused rat and mouse small intestinal studies were
conducted with permission from the Danish Animal
Experiments Inspectorate (2018-15-0201-01397) and our local
Institutional Animal Care and Use Committee (Department of
Experimental Medicine, Protocol nr. P18-555 and P-20-067).
Experiments were performed in accordance with the guidelines
of the Danish legislation governing animal experimentation
(1987) and the National Institutes of Health (publication
number 85-23) and the European Convention for the
Protection of Vertebrate Animals used for Experimental and
other Scientific Purposes (Council of Europe No. 123,
Strasbourg 1985).August 2021 | Volume 12 | Article 690387
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Mediated by Activation of Rat and
Human MC4R
COS-7 cells were transiently transfected using the calcium-
phosphate precipitation method (15) with either human MC4R
or rat MC4R. Since MC4R primarily is a Gas-coupled receptor
(16) intra-cellular cAMP production was used as marker of
receptor activation. Procedures are described in details
elsewhere (17). In brief, the cells were seeded in white 96-well
plates at a density of 3.5 ∗ 104 per well one day after the
transfection. The following day, the cells were washed twice
with HEPES-buffered saline (HBS) and incubated with HBS and
1 mM 3-isobutyl-1-methylxanthine (IBMX) for 30 min at 37°C
(95% O2, 5% CO2). In order to determine agonistic activities,
alpha-MSH and NDP-alpha-MSH were added in increasing
concentrations and incubation continued for 30 min at 37°C.
In order to determine the antagonistic properties of HS014, the
cells were pre-incubated for 10 min with increasing
concentrations of HS014 followed by addition of fixed
concentrat ions of alpha-MSH or NDP-alpha-MSH,
corresponding to 60–80% max activity, and incubated for an
additional 20 min (18). After incubation, cells were thoroughly
washed and then lysed. Determination of cAMP was done with a
HitHunterTM cAMP XS assay (DiscoverX, Herlev, Denmark)
according to manufacturer’s instructions.
Isolated Perfused Mouse and Rat
Small Intestine
MaleWistar rats (~250 g) and male C57BL/6JRj mice (~28 g, 11–
12 weeks) were purchased from the Janvier Labs (Le Genest-
Saint-Isle, France). Mice and rats were housed with ad libitum
access to standard chow and water following a 12:12 h light:dark
cycle and were acclimatized for a least a week before
experiments. On the day of experiment, rats and mice were
transferred to our perfusion facility and anesthetized with a
subcutaneous injection of hypnorm/midazolam (rats) (0.3 ml/
100 g body weight, per ml: 0.08 mg fentanyl, 2.5 mg fluanisone,
0.45 mg Methyl Parahydroxybenzoate, 0.05 mg Propyl
Parahydroxybenzoate, Midazolam: 1.25 mg, Matrix
Pharmaceut ica l s , He l l e rup , Denmark) or wi th an
intraperitoneal injection of Ketamine/Xylazine (0.1 ml/20 g)
(90 mg/kg Ketamine, Ketaminol Vet, MSD Animal Health; 10
mg/kg Xylazine, Rompun Vet., Bayer Animal Health)
respectively, to block the activity of pain sensing nerves and to
induce surgical anesthesia. For distal perfusions, the rat or mouse
was placed on a heated operating table (37°C), the abdominal
cavity was opened by a mid-line incision and the large intestine
was excised after tying off the supplying vasculature.
Furthermore, the upper half of the small intestine was
removed. In the rat, the lower half of the small intestine (~50
cm) was retained and perfused in situ after insertion of a catheter
into the upper mesenteric artery, while perfusion effluent was
collected through a catheter inserted in the portal vein. The
mouse intestine (10–12 cm of the distal part) was perfused by a
slightly different pathways (since the upper mesenteric artery isFrontiers in Endocrinology | www.frontiersin.org 3too small to cannulate), perfusing retrogradely through a
catheter inserted in the abdominal aorta. To avoid perfusion of
other abdominal organs, the spleen and stomach was removed
and the kidneys were excluded from the circulation by tying off
the renal arteries. For the perfusion of the proximal small mouse
intestine the procedure was the same, however the distal part of
the intestine was removed and the most proximal part (~11–12
cm) of the small intestine was left untouched. The length of the
retained intestine varied little between experiments (coefficient of
variation <15%). The perfusion buffer consisted of a Krebs–
Ringer bicarbonate buffer supplemented with 0.1% (w/v) BSA
(fraction V), 5% (w/v) dextran T-70 [to balance oncotic pressure
(Pharmacosmos, Holbaek, Denmark)], and 3.5 mmol/L glucose,
and 5 mmol/L pyruvate, fumarate, and glutamate as well as 10
µmol/l 3-isobutyl-1-methylxanthine (IBMX, cat. no. I5879,
Sigma Aldrich, Brøndby, Denmark) and 2 ml/L (rat) or 5 ml/L
(mouse) Vamin (a mixture of essential and nonessential amino
acids; Fresenius Kabi, Bad Homburg, Germany). pH was
adjusted to 7.4–7.5. A vascular flow rate of 7.5 ml/min was
used for rat perfusions and 2.5 ml/min for mouse perfusions.
Luminal stimulations was done at a flow rate of 2.5 ml/min in
rats and 0.035 ml/min in mice. Prior to perfusions, the perfusion
buffer was gassed with 95% O2 and 5% CO2. Perfusions were
carried out using a UP100 Universal Perfusion System from
Hugo Sachs (Harvard Apparatus, March Hugstetten, Germany),
which includes heating to 37°C.
Test Compounds
Nle(4),D-Phe(7)]a-melanocyte-stimulating hormone (NDP-a-
MSH) was from Phoenix Pharmaceuticals, Inc. (Cat. no. 043-06,
Burlingame, CA, USA). HS014 was from Tocris (Cat. no. 1831,
Abingdon, UK). Human a-MSH, D-glucose and bombesin were
from Sigma Aldrich (Cat. no. M4135, G8270 and B4272,
Brøndby, Denmark).
MC4R Expression From Mouse and
Human L-Cell RNA Sequencing Datasets
All RNA sequencing data were analyzed using R (version 4.0.3).
Datasets included in this analysis are listed in the Table 1 below.
Bulk RNA sequencing datasets were converted into DESeq2
format (1.30.0; Bioconductor). Transcript lengths were obtained
from biomaRt (2.42.1; Bioconductor) and imported into the
DESeq2 dataset. Fragments per kilobase million (FPKM) values
were exported using DESeq2’s in-built function (fpkm). Bulk
RNA-seq data presented in heat maps are log2 (average FPKM
across samples).
Single-cell datasets were converted into Seurat format (4.0.2;
Bioconductor), filtering for only cells with counts for >200 genes,
and only genes with counts for >3 cells. Data were normalized to
FPKMmanually using gene transcript lengths and total reads per
sample. For data from Billing et al. (20), all cells were first
clustered to obtain five populations as originally published, and
data filtered to the two L-cell populations (Insl5 and Nts). Single-
cell RNA-seq data presented in heat maps are log2 (average
FPKM across cells).August 2021 | Volume 12 | Article 690387
Kuhre et al. MC4-Receptor Activation and GLP-1 SecretionRT-qPCR Based Assessment of MC4R
Expression in Mouse Small Intestine
cDNA was analyzed from previously described mouse villus and
crypt L-cell samples in the duodenum (19), and mouse ileal L-
cell samples (8), including corresponding negative samples.
Subsequent RT-qPCR was carried out as previously described
(22), with three samples per region, and three technical replicates
per sample. The following probes obtained from Life
Technologies (Paisley, UK) were used: Gpr119: Mm00731497_s1;
Mc4r: Mm00457483_s1. Relative expression of each gene of
interest was calculated by comparison to expression of the
housekeeper b-actin. The cycle threshold (CT) per gene was
calculated as the mean over technical replicates, and the
difference (DCT) calculated by subtracting each gene CT from b-
actin CT. Relative gene expression is represented in figures as 2DCT.Biochemical Measurements
Total GLP-1 concentrations in venous effluents were quantified
using an in-house RIA (code: 89390) (23). The assay employs an
antibody that exclusively reacts with the amidated C-terminal
domain of GLP-1 and thus measures intact GLP-1 (7–36 amide)
and the primary metabolite (9–36 amide) with equal potency and
it also measures cleaved sequences potentially resulting from
mid-site cleavage [e.g. cleaved by neprilysin (24)]. Samples were
assayed non-extracted and concentrations were calculated by a
four-parameter interpolation to a standard curve containing
synthetic GLP-1 7–36 amide (H-6795-GMP, Bachem,
Bubendorf, Switzerland) ranging from 5 to 320 pmol/L. I125-
labeled GLP-1 7–36 amide (a gift from Novo Nordisk A/S,
Bagssværd, Denmark) was used as tracer. The standards were
prepared in perfusion buffer and run in parallel with the samples.
The experimental detection limit was 1 pmol/L and the
coefficient of variation was <6% at 20 pmol/L, allowing
detection of secretion rates down to 2.5 fmol/min (mouse) and
7.5 fmol/min (rat).
Data Presentation and Statistical Analysis
GLP-1 total output (fmol/min) was calculated by multiplying
perfusion flow (mouse: 2.5 ml/min and rat: 7.5 ml/min) with the
GLP-1 concentration in the perfusion effluents (presented in fmol/
L). Hormone outputs are presented as means ± SEM. To test for
statistical significance of responses, total GLP-1 outputs wereFrontiers in Endocrinology | www.frontiersin.org 4calculated by summing up the outputs during the entire period of
stimulus administration (e.g. 15 min of NDP-a-MSH
administration); these outputs were compared to the total GLP-1
outputs from the preceding basal period which was of the same
duration in case of the rat experiments. In the mouse experiments,
the length of the initial baseline period was 10 min whereas
stimulation periods were 15 min. In this case, outputs are
expressed as average outputs within respective periods (fmol/
min). Baseline outputs were calculated based on a similar number
of samples from the baseline leading up to first period of test
compound stimulation constituting the first baseline and the second
baseline being derived from the eight samples immediately before
stimulus administration and last seven samples during subsequent
baseline period (immediately before BBS stimulation). Baseline
outputs were calculated in this manner to control for potential
baseline drift over the course of the experiment. EC50 and IC50
values for MC4R activation/inhibition in the in vitro studies were
calculated from four-parameter logarithmic fitting. Statistical
calculations were performed using GraphPad Prism 7 software
(La Jolla, CA, USA), employing one-way ANOVA for repeated
measurements followed by Tukey multiple comparison test or
Student t-test as indicated in the figure legends. P <0.05 was
considered significant. Prior to testing, a D’Agostino–Pearson
omnibus normality test was performed to confirm Gaussian
distribution of the data. Graphs were constructed in GraphPad
Prism 7 (La Jolla, CA, USA) and figures were prepared in an Adobe
Illustrator (Adobe Systems Incorporated, San Jose, CA, USA).RESULTS
In Vitro Determination of Activity for alpha-
MSH, NDP-alpha-MSH and HS014 on Rat
and Human MC4R
In order to use appropriate concentrations of MC4R agonists and
antagonist in the experiments on isolated perfused small
intestine, we first determined the potencies of alpha-MSH (an
endogenous MC4R agonist) and NDP-alpha-MSH (a MC4R
super-agonist) in cAMP measurement experiments on rat and
human MC4R transfected into COS-7 cells. We moreover
determined the inhibitory properties of the MC4R antagonist,
HS014 on the two MC4R’s. The rat MC4R was activated byTABLE 1 | RNA sequencing data sets used for investigation of L-cell expression of MC4R.
Citation RNA sequencing Species Region Number of cells/samples
Glass et al. (19), Molecular Metabolism Single cell Mouse Duodenum 259
Roberts et al. (8), Diabetes Bulk Mouse Duodenum 2
Ileum 3
Colon 3
Roberts et al. (8), Diabetes Bulk Human Jejunum 11
Ileum 2
Billing et al. (20), Molecular Metabolism Single cell Mouse Large intestine (colon and rectum) 635
Goldspring et al. (21), Cell Reports Bulk Human Ileum organoids 8August 2021 | Volume 12 | Article 690387
Kuhre et al. MC4-Receptor Activation and GLP-1 Secretionalpha-MSH and NDP-alpha-MSH with EC50 values of 1.5 ×
10−8 M and 9.1 × 10−11 M (LogEC50 −7.8 ± 0.06 and −10.04 ±
0.5, n = 3). NDP-alpha-MSH had an Emax that was
approximately 120% of that of alpha-MSH (Figure 1A, n = 3).
HS014 [often described as an MC4R antagonist (25, 26)] was in
our setup a partial agonist of rat MC4R with an EC50 of 1.5 ×
10−8 M (LogEC50 −7.8 ± 0.54 here, n = 3) and Emax of around
40% of alpha-MSH Emax. Activation of human MC4R showed
similar relationships but with potencies that were slightly lowerFrontiers in Endocrinology | www.frontiersin.org 5for all three compounds (alpha-MSH, 8.4 × 10−8 log EC50 7.1 ±
0.1, NDP-alpha-MSH, 2.8 × 10−10 log EC50 −9.6 ± 0.2, and
HS014, 3.5 × 10−8 log EC50 7.5 ± 0.8 (Figure 1D, n = 3). The
antagonistic property of HS014 on the rat MC4R was tested
using submaximal concentrations of NDP-alpha-MSH or alpha-
MSH corresponding to 60–80% of Emax. Here, an increasing
concentration of HS014 revealed inhibition of agonist-induced
activity with IC50 values of 2.6 × 10
−8 M and 6.1 × 10−9 M (log
IC50 7.6 ± 0.3 and −8.2 ± 0.2) (Figures 1B, C, n = 3). Again,A B
D E F
C
FIGURE 1 | Characterization of agonistic properties of alpha-MSH and NDP-alpha-MSH and antagonizing effects of HS014 on rat and human MC4R in transfected
COS-7 cells. Concentration–activation relationship on rat (A) and human (D) MC4R are shown in response to alpha-MSH (black filled circles with black line), NDP-
alpha-MSH (gray circles with gray line) and HS014 (open triangle with staged black line). Concentration-dependent antagonizing effects of HS014 (a partial agonist)
on rat (B, C) and human (E, F) MC4R activation in response to agonist concentrations that result in sub-maximal activation of the receptors. IC50-values are
indicated above respective graphs. EC50 values for (A): alpha-MSH = 1.5 × 10
−8 M, NDP-alpha-MSH = 9.1−11 M, HS014 = 1.5 × 10−8 M. EC50 values for (×): alpha-
MSH = 8.5 × 10−8 M, NDP-alpha-MSH = 2.8 × 10−10 M, HS014 = 3.5 × 10−8 M. Data are presented as means ± SEM, n = 3.August 2021 | Volume 12 | Article 690387
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(Figures 1E, F, n = 3).
MC4R Expression in Mouse and
Human L-Cells
To investigate whether any effects of systemic MC4R agonist
administration on plasma GLP-1 concentrations in mice (11, 12)
and humans (14) may result from direct MC4R-activation at theFrontiers in Endocrinology | www.frontiersin.org 6level of the L-cell, we investigated MC4R expression in mouse and
human L-cells by reanalyzing raw data from both bulk RNA
sequencing (mouse and human) and single cell RNA sequencing
(mouse) (8, 19–21) as well as by qPCR (mouse). In mice, MC4R
was expressed at higher levels than the other melanocortin
receptor isoforms and, as previously reported, was enriched in
L-cells relative to the surrounding epithelium (Figure 2A, left
panel), which is predominantly constituted from absorptiveA
B
FIGURE 2 | Expression of Mc4 receptor in mouse and human L-cells. (A) Heatmap of melanocortin receptor genes in L-cells from multiple RNA sequencing
datasets, including corresponding negative samples where available. Each column is a dataset, the left panel being datasets in mouse, and the right in human.
Datasets are labeled per publication [a Glass et al. (19); b Roberts et al. (8); c Billing et al. (20); d Goldspink et al. (21)], per region of the gut (shades of blue, where
the distal gut is darker blue; * colon and rectum), and for L-cell positive or negative population (+ = green, − = gray). Data is plotted as log2 (mean fragments per
kilobase million, FPKM), increasing from blue ! white ! red. Data from Billing et al. was calculated as the average across both L-cell clusters (Insl5 and Nts), while
data from Glass et al. was calculated as the average across all cells. (B) Relative expression of Gpr119 and Mc4r in L-cells from duodenum (duo) villus and crypt,
and ileum (n = 3 mice). Samples include both L-cells (+) and their corresponding negatives (−). Values are 2DCT relative to b-actin.August 2021 | Volume 12 | Article 690387
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in the large intestine, lower than the expression of other L-cell-
expressed GPCRs (GPR119 and bile acid receptor GPBAR1) with
established GLP-1 secretory potential. qPCR of mouse duodenum
and ileum further demonstrated enrichment ofMc4r in duodenal,
but not ileal, L-cells, and the low expression relative to Gpr119
(Figure 2B). By contrast, in humans,MC4R was barely detectable
in the intestinal epithelium, and insteadMC1Rwas detectable and
enriched in small intestinal L-cells (Figure 1A, right panel).
Although MC1R expression levels were comparable to GPR119
and GPBAR1 in acutely isolated human L-cells, in ileal organoid
cultures expression levels of MC1R were much lower.
Direct Effects of NDP-alpha-MSH on
GLP-1 Secretion From Isolated Perfused
Mouse and Rat Small Intestine
As the relatively low Mc4r expression, compared with other
established pro-secretory GPCRs such as Gpr119, puts into
question that GLP-1 responses to systemic MC4R agonists
observed in vivo derive from direct actions on the L-cell, other
stimulatory intestinal pathways could drive GLP-1 secretion
secondary to intestinal MC4R activation. To assess this
possibility, we performed studies on isolated and perfused
mouse and rat small intestine.
In isolated perfused mouse small intestine—upper half—total
GLP-1 secretion during the first baseline period (1–10 min) was
on average 25 ± 4.0 fmol/min. Luminal NDP-a-MSH infusion (1
µmol/L) had no effects on GLP-1 output (average secretion: 23 ±
4.8 fmol/min, P = 0.98, n = 6, Figures 3A, B). Similarly, vascular
NDP-a-MSH administration (1 µmol/L) had no effect on GLP-1
secretion (average outputs; preceding baseline = 50 ± 4.8 fmol/
min, during NDP-a-MSH administration = 45.9 ± 4.3 fmol/min,
P = 0.90, n = 6, Figures 3A, B). Vascular administration of
bombesin (positive control) at the end of experiments robustly
increased GLP-1 output (Figures 3C, D).
Similar secretory dynamics were found when isolating and
perfusing the distal part of the mouse small intestine. In this case,
average outputs during initial baseline was 17.4 ± 2.4 fmol/min,
whereas average output during luminal administration with
NDP-a-MSH (1 µmol/L) was 15 ± 2.2 fmol/min, P = 0.75).
Consistent with data from the perfused proximal part of the
small intestine, vascular administration of NDP-a-MSH at the
same dose also did not stimulate GLP-1 output (average output
during stimulation: 26 ± 2.0 fmol/min vs. average output during
preceding baseline: 24 ± 2.1 fmol/min. P = 0.37). Vascular
administration of bombesin (positive control) at the end of
experiment, again, robustly increased GLP-1 output (Figure 3C).
In isolated perfused rat distal small intestine, total GLP-1
secretion was equally unaffected by luminal and vascular NDP-a-
MSH instillation (1 µmol/L; 100-fold higher than the
concentration needed to fully activate rat MC4R shown in the
in vitro studies). In this case, total GLP-1 output was initially (1–
15 min) 1.1 ± 0.2 pmol and 1.1 ± 0.1 pmol during subsequent
luminal NDP-a-MSH administration (P >0.99, n = 6, Figures 3E,
F). Similarly, vascular (intra-arterial) administration of NDP-a-
MSH had no effects on GLP-1 secretion (total output duringFrontiers in Endocrinology | www.frontiersin.org 715 min of stimulation = 1.9 ± 0.2, total output during immediate
preceding baseline period (15 min) = 1.9 ± 0.3 pmol, P = 0.98,
Figures 3E, F). Baseline secretion drifted slightly upwards during
the course of the experiment (P <0.01) in a manner that was
unrelated to the administration of test compounds.
Effects of NDP-alpha-MSH and HS014 on
Glucose-Stimulated GLP-1 Secretion From
Isolated Perfused Rat Small Intestine
Luminal glucose is a powerful stimulus for GLP-1 secretion. To
investigate if the GLP-1 response to glucose is partially driven by
MC4R activity, we stimulated the perfused rat small intestine
twice with luminal glucose and blocked MC4R activity (by intra-
arterial HS014 infusion, 30 nmol/L; >4 fold higher than the IC50
for alpha-MSH-stimulated MC4R activation) during the second
glucose stimulation (Figures 3G, H). In a separate line of control
experiments we applied the same protocol but without HS014
infusion. In both experiments, the first glucose stimulation
resulted in a robust and immediate increase in GLP-1 secretion
which was similar in effect size (total GLP-1 outputs during
respective baselines and luminal glucose administration (in both
cases 15 min in total) were: control experiment: Baseline = 1.8 ±
0.2 pmol, luminal glucose = 4.8 ± 0.34 pmol, P <0.001, and in the
glucose + HS014 experiment: Baseline = 2.0 ± 0.5 pmol, luminal
glucose = 5.6 ± 1.0 pmol, P = 0.01, Figures 3G, H, n = 6). The
second glucose response in the control experiment tended to
have lower initial peak values compared to the first glucose
response, but total secretion during glucose administrations was
not different: first response = 4.8 ± 0.3 fmol, second response =
4.7 ± 0.7 fmol, P >0.99, Figure 3H). Administration of HS014
together with glucose had no effects on the glucose response.
Glucose again robustly increased GLP-1 output and the total
output with HS014 was similar to the total output during the first
glucose stimulation (total GLP-1 outputs (15 min) were: baseline
= 3.2 ± 0.6 pmol, glucose + HS014 = 5.4 ± 1.1 pmol, P <0.05
between baseline and glucose response, P = 0.98 between glucose
responses, n = 6, Figure 3I). Thus, the total secretory outputs
during the second glucose administration were similar between
the control experiment and the experiment with co-
administration of HS014 (P = 0.62, n = 6, Figure 3J).DISCUSSION
GLP-1 based therapy has proven effective for type-2-diabetes
treatment as well as for weight loss. The molecular mechanisms
responsible for GLP-1 secretion have been investigated eagerly
during the last two decades, and the understanding of the
molecular mechanisms underlying macronutrient stimulated
GLP-1 secretion has improved (5). Less is known about neural,
paracrine and endocrine regulation of GLP-1 secretion. Several
stimulators acting via G-protein-coupled receptors have been
investigated for their ability to stimulate L-cell secretion,
including agonists of the bile-acid sensitive receptor GPBAR1
or of the different fatty-acid receptors (22, 27–30). The direct
inspiration for the current study came from studies in mice andAugust 2021 | Volume 12 | Article 690387








FIGURE 3 | MC4 receptor activity neither controls GLP-1 secretion from isolated perfused mouse and rat small intestine per se nor inhibits glucose-stimulated GLP-
1 secretion. GLP-1 (total) outputs are shown in response to luminal or vascular NDP-a-MSH administration in mice (A–D) or rats (E, F) (1 µM in both cases) or in
response to luminal glucose (20%, w/v) with or without co-administration of the MCR-4 partial agonist HS014 (rats, 30 nM) (G, H). Outputs are presented as min–
min concentrations (A–D, fmol/min) or as total outputs during respective experimental periods (each 15 min of duration) (E–J, pmol). Dots in (B, D, F, H, I, J)
represent outputs from different experiments. Data are shown as means ± SEM. Statistical significance was tested by Student t-test (H) or by One-way ANOVA for
repeated measurements followed by Tukey post hoc test (remaining). P <0.05 was considered significant. *P <0.05, ***P <0.001. n (A–F) = 6. Black color in (G) are
the control glucose experiment, gray line is the glucose + HS014 experiment.Frontiers in Endocrinology | www.frontiersin.org August 2021 | Volume 12 | Article 6903878
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and/or LY2112688 (an orthosteric MC4R agonist), increased
plasma GLP-1 and PYY concentrations in mice after intra-
peritoneal injection (11, 12), and that three days of continuous
subcutaneous infusion with another MC4R agonist (RM-493)
increased plasma GLP-1 concentrations in humans (14). In the
mouse study, the underlying mechanism for this response (11)
appeared to involve direct activation of L-cell MC4R’s, since
MC4R was found to be the second most highly enriched G-
protein-coupled receptor expressed by L-cells compared to non-
enteroendocrine cells from same intestinal site (11). Data on
GLP-1 secretion was, however, not provided, but the authors
showed in Ussing chamber experiments on colonic mucosa from
mice and humans that alpha-MSH administration to the vascular
compartment increased PYY-dependent short circuit currents.
The current study was, therefore, designed to investigate whether
the reported stimulatory effects of MC4R agonist in vivo may
result from direct effects on the L-cell, from effects on other gut
cells acting within the gut to stimulate GLP-1 secretion, or from
extra-intestinal factors. To investigate the structural basis for a
direct effect of MC4R activation on GLP-1 secretion, we
quantified Mc4r expression levels in L-cells from mice and
humans, using a collection of publicly available RNA
sequencing data bases that include expression levels in L-cells
from the mouse duodenum, ileum and colon, and human
jejunum and colon, and from non-L-cells from same
anatomical sites (a population that is presumably dominated
by enterocytes) to assess for potential L-cell enrichment.
Furthermore, in the mouse we quantified Mc4r expression in
isolated L-cells and non-L-cells by RT-qPCR from the
duodenum and ileum. The RNA sequencing data showed some
L-cell enrichment but relatively low absolute expression of Mc4r
across the mouse intestine. Expression was detected in a small
subset of investigated duodenal cells (39%), similar in size to the
subset expressing Gpr119 (34%), but expression levels of Mc4r
were 1.25-5 times lower than those of Gpr119. This is in direct
support of previous findings in mouse proximal small intestine
that Mc4r is enriched in GLP-1-expressing cells (11), and
expressed at levels approximately five times lower than Gpr119
(11, 31). This lower expression ofMc4r compared to Gpr119 was
confirmed by RT-PCR in duodenal L-cells, whereas in ileal L-
cells Mc4r expression was barely detectable. In human L-cells,
MC4R expression was similarly hardly detectable and not
enriched compared to non-L-cells, whereas we found enriched
expression of MC1R. Collectively, the expression levels of all
MC1-5R’s were in both species either barely detectable or low
when compared with other Gs-coupled receptors such as Gpr119
and Gpbar1, which have been shown to robustly stimulate GLP-1
secretion upon activation (22, 28, 31–33).
The regional differences in Mc4r expression could suggest
that the increased plasma GLP-1 in response to MC4R agonists,
if mediated by direct L-cell stimulation, could be restricted to
stimulation of L-cells in the very upper part of the small intestine
(duodenum). This anatomical site is, however, relative sparse in
L-cells and GLP-1 content (34–41), suggesting that this
anatomical site contributes minimally to total circulating GLP-Frontiers in Endocrinology | www.frontiersin.org 91 levels. Furthermore, Panaro et al. (12) have shown that selective
knock-out of proglucagon from the distal intestine (ileum and
colon, using a Cdx2-Cre x gcg-floxed model) was sufficient to
essentially abolish GLP-1 elevation in response to intraperitoneal
administration of the MC4R-agonist LY2112688.
As the relative contribution of different intestinal sites in
terms of total GLP-1 secretion are not easily assessed in vivo, and
since secretion in vivo may also be regulated by central and
neural signaling, it was essential for our functional studies to use
an experimental model that would allow study of regional
secretion while excluding extra-intestinal signaling but being
physiologically relevant. We therefore based our studies on
isolated perfused mouse and rat small intestine preparations,
which allow studies of GLP-1 secretion at high time resolution
and with almost complete experimental control. At the same
time, these models maintain epithelial polarization and
vasculature as well as local enteric innervation and paracrine
interrelationships (42). Despite detectable Mc4r expression in
upper and, if somewhat lower expression, in lower small
intestinal L-cells, we were, however, unable to detect any L-cell
stimulation by the MC4R super-agonist NDP-alpha-MSH from
either upper or lower small intestinal preparations. This suggests
that the previously reported in vivo observations either cannot be
simulated in this preparation, arise solely from stimulation of
MC4R on colonic L-cells or involve MC4R located outside the
intestinal preparation. GLP-1 secretion can readily be stimulated
from perfused small intestinal preparations by e.g. GPBAR1
agonists (22, 28), arguing that in principle Gs-coupled receptor
stimulated GLP-1 secretion is observable in this preparation. It is
possible that the Mc4r expression, being somewhat lower than
Gpr119 and Gpbar1 expression, is insufficient to elicit a secretory
response. Given that colonic L-cell Mc4r expression is at similar
relatively low levels as observed in duodenal L-cells it seems thus
unlikely that direct stimulation of colonic L-cells alone is
underlying in vivo GLP-1 responses to MC4R-agonists,
although GLP-1 and PYY secretion from ex vivo incubated
human colonic mucosal specimens was reported to increase in
response to MC4R agonists (13). Modulation by extra-intestinal
MC4R not present in the preparation is a possibility that should
be addressed in future research, especially, given the apparent
absence of MC4R expression in human L-cells.
While our combined data therefore suggested that intestinal
MC4R activation does not in itself drive GLP-1 secretion in the
mouse and rat small intestine, MC4R signaling in the gut could
potentially still potentiate GLP-1 secretion stimulated via other
pathways.We therefore next investigated if the GLP-1 response to
one of the most powerful and well characterized stimuli—luminal
glucose—was affected by simultaneous activation/partial
inhibition of MC4R activity. For these studies, we isolated and
perfused the distal part of the rat small intestine and stimulated
the perfused preparation with luminal glucose with or without
simultaneous intra-arterial NDP-alpha-MSH or HS014 infusion.
The latter is a frequently described MC4R antagonist but, as we
show here in our in vitro studies, actually acts as a partial agonist
at certain concentrations. However, at the concentration used in
our perfusion experiments (30 nM), HS014 acts functionally as anAugust 2021 | Volume 12 | Article 690387
Kuhre et al. MC4-Receptor Activation and GLP-1 Secretionantagonist. Consistent with some of our previous studies, luminal
glucose infusion increased GLP-1 secretion from isolated
perfused rat small intestine 2–3 fold (43, 44), but neither NDP-
alpha-MSH (at 100-fold higher than Emax) nor HS014 affected the
response, despite the concentration of the latter being, based on
our pharmacology studies, well above the dose expected to be
required [two to three times higher than the IC50 of alpha-MSH
on rat MC4R, and corresponding to the reported IC50 on human
MC4R (3–4 nM) (45)]. Although, frequently reported to be a
specific MC4R antagonist, HS014 also antagonizes MC1R, MC3R
and MC5R but with IC50’s that for the human receptor-subtypes
are 15–200 fold higher than the IC50 for MC4R (~55 nM) (45).CONCLUDING REMARKS
The expression data and perfusion data we report here do not
support that MC4R-activation in the small intestine or at the
level of the small intestinal L-cells should affect GLP-1 secretion.
Nevertheless, an important question that remains to be clarified
with regards to the potential importance of gut MC4R signaling
for GLP-1 secretion is the potential source of melanocortin
receptor ligands in the intestine. Peptides of intestinal bacterial
origin with melanocortin receptor activity have been reported
(46), but these are unlikely to reach high concentrations in the
small intestine, where we found the highest Mc4r expression in
the mouse. It is questionable whether plasma alpha-MSH would
activate L-cell melanocortin receptors in humans since we found
the EC50 for alpha-MSH on humanMC4R to be 85 nM, while the
plasma concentrations of alpha-MSH in humans are more than
5,000 fold lower (~4–15 pM (47–49). Others have found the EC50
of a-MSH on human MC4R to be even higher; ~900 nM (45).
POMC positive cells have, however, been reported in the human
intestine and although alpha-MSH and ACTH were not detected,
beta-MSH was (35, 50), suggesting that a local intestinal source
of MC4R agonist may exist. The functional role of such a
potential source and the control regulating its secretion
warrants further investigation.DATA AVAILABILITY STATEMENT
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